¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell loss factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
  • crescent cell anemia
    Ãʽ´ÞÀûÇ÷±¸ºóÇ÷
  • crypt cell
    âÀÚ»ù¼¼Æ÷, ¿ò¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • cell
    ¼¼Æ÷
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell bank
    ¼¼Æ÷ÀºÇà
  • cell body
    ¼¼Æ÷ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell hybridization
    ¼¼Æ÷ºÎÇÕÈ­, ¼¼Æ÷ÇÏÀ̺긮µåÈ­
  • cell inclusion
    ¼¼Æ÷Æ÷ÇÔ¹°
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell mass
    ¼¼Æ÷µ¢ÀÌ
  • cell membrane
    ¼¼Æ÷¸·
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëÄ¡, Ç÷±¸´ëÄ¡
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • T cell hybridoma
    T¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • T cell immunity
    T¼¼Æ÷¸é¿ª
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • T cell lymphoma
    T¼¼Æ÷¸²ÇÁÁ¾
  • T cell receptor
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
  • T-cell
    T-¼¼Æ÷
  • T-cell differentiation
    T-¼¼Æ÷ºÐÈ­
  • Th cell
    Th¼¼Æ÷, Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • Ts cell
    ¾ïÁ¦T¼¼Æ÷
  • Tzanck cell
    Á¤Å© ¼¼Æ÷
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • accessory cell
    º¸Á¶¼¼Æ÷, ºÎ¼ö¼¼Æ÷
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • factor
    ÀÎÀÚ
  • factor B
    B ÀÎÀÚ
  • factor B
    BÀÎÀÚ
  • factor D
    D ÀÎÀÚ
  • factor D
    DÀÎÀÚ
  • factor H
    H ÀÎÀÚ
  • factor H, B1H
    HÀÎÀÚ
  • factor I
    I ÀÎÀÚ
  • factor I
    IÀÎÀÚ
  • factor II
    Á¦ II ÀÎÀÚ
  • factor IX
    Á¦ IX ÀÎÀÚ
  • factor IX transfusion
    Á¦ IX ÀÎÀÚ¼öÇ÷
  • factor IXa
    Á¦ IXaÀÎÀÚ
  • factor V
    Á¦ V ÀÎÀÚ
  • factor VII
    Á¦ VII ÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • oligomycin-sensitivity-conferring factor
    ¿Ã¸®°í¸¶À̽а¨¼ö¼ººÎ¿©ÀÎÀÚ(Êïáôàõݾæ¨ì×í­)
  • particle scattering factor
    ÀÔÀÚ »ê¶õÀÎÀÚ(Ø£í­ß¤Õ¯ì×í­)
  • pellagra-preventaive factor
    Æç¶ó±×¶ó ¿¹¹æÀÎÀÚ(çãÛÁì×í­)
  • permeability factor
    Åõ°ú ÀÎÀÚ(÷âΦì×í­)
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­)
  • plasma thromboplastic factor
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ(úìíìúìîûû¡à÷ì×í­)
  • plasma thromboplastic factor B
    Ç÷Àå Ç÷ÀüÇü¼ºÀÎÀÚ B
  • platelet-activating factor
    Ç÷¼ÒÆÇȰ¼º ÀÎÀÚ(úìá³÷ùüÀàõì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • PP factor
    PP ÀÎÀÚ(ì×í­)
  • preexponential factor
    Áö¼ö(ò¦â¦)¾ÕÀÚ¸® ÀÎÀÚ(ì×í­)
  • protein factor
    ´Ü¹éÁú ÀÎÀÚ(Ó±ÛÜòõì×í­)
  • protein release factor
    ´Ü¹éÁú ¹æÃâÀÎÀÚ(Ó±ÛÜòõÛ¯õóì×í­)
  • protein synthesis factor
    ´Ü¹éÁú ÇÕ¼ºÀÎÀÚ(Ó±ÛÜòõùêà÷ì×í­)
  • prothrombin factor
    ÇÁ·ÎÆ®·Òºó ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
LOC laxative of choice; level of consciousness; liquid organic compound; locus of control; loss of consc...
LOH loop of Henle; loss of heterozygosity
LOM left otitis media; limitation of motion; loss of motion
LOR long open reading frame; lorazepam; loricrin; loss of righting reflex
LP labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
HB-EGF Heparin binding epidermal growth factor-like growth factor
HB-EGF Heparin-binding epidermal growth factor (EGF)-like growth factor
HGF Hepatocyte Growth Factor-Scatter Factor
HGF-SF Hepatocyte Growth Factor-Scatter Factor
SF/HGF Scatter factor/hepatocyte growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • cell count
    ¼¼Æ÷ ¼ö
    ´ÜÀ§ ºÎÇÇ´ç Æ÷ÇԵǾî ÀÖ´Â ¼¼Æ÷ ¼ö·Î¼­ º¸Åë ´ÜÀ§ ºÎÇÇ´ç Ç÷¾×¿¡ Æ÷ÇԵǾî ÀÖ´Â ÀûÇ÷±¸¿Í/ȤÀº ¹éÇ÷±¸¸¦ ¸»ÇÑ´Ù.
  • cell culture biocompatibility test
    ¼¼Æ÷ ¹è¾ç »ýü ÀûÇÕ¼º °Ë»ç¹ý
  • cell cycle-non specific
    ¼¼Æ÷ Áֱ⠺ñƯÀ̼º Á¦Á¦
  • cell death
    ¼¼Æ÷»ç
    ¼¼Æ÷°¡ Á׾´Â °úÁ¤¿¡¼­ »ýü ÀÛ¿ëÀÌ ¼¼Æ÷ ¼öÁØ¿¡¼­ Áß´ÜµÈ ÁöÁ¡. ¼¼Æ÷»ç´Â Á¶Á÷À̳ª Àå±â¸¦ Àå±â ÀÌ½Ä °ø¿©Ã¼·Î »ç¿ëÇÏ´Â °Í¿¡ ¾Õ¼­ ÀϾ´Ù.
  • cell differentiation
    ¼¼Æ÷ ºÐÈ­
    ¼¼Æ÷µéÀÌ Á¶Á÷ÀÇ ´Ù¾çÇÑ ±âº» ¼¼Æ÷ ´ÜÀ§·Î ¼ºÀåÇÏ´Â °Í. »óÇǼ¼Æ÷, ½Å°æ¼¼Æ÷
  • cell division
    ¼¼Æ÷ ºÐ¿­
    ÇϳªÀÇ ¼¼Æ÷°¡ µÑ ÀÌ»óÀ¸·Î ³ª´©¾îÁö´Â ÀÏ. º¸Åë ÇÙ ºÐ¿­ÀÌ ¼¼Æ÷Áú ºÐ¿­º¸´Ù ¸ÕÀú ÀϾ´Ù. ÀÌ ÇÙ ºÐ¿­Àº ´ëºÎºÐÀÇ °æ¿ì À¯»çºÐ¿­À̸ç, À¯»çºÐ¿­Àº ¿°»öüÀÇ ºÐ¹è¿Í °°Àº Áß¿äÇÑ ÀÏÀ» ÇÑ´Ù. ü¼¼Æ÷ ºÐ¿­°ú °¨¼ö ºÐ¿­ ¾çÂÊ¿¡¼­ º¸ÀδÙ. ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­Àº Àü±â, Áß±â, Èıâ, ¸»±â·Î ³ª´©¾îÁø´Ù. ºÐ¿­ °á°ú ¸¸µé¾îÁø µþ ¼¼Æ÷µéÀº ¸ð¼¼Æ÷¿Í µ¿ÀÏÇϸç, ÇÙ³»ÀÇ À¯Àü¹°ÁúÀº Á¤È®ÇÏ°Ô º¹Á¦µÇ¾î 2°³ÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁ® µé¾î°£´Ù. °¨¼ö ºÐ¿­Àº »ý½Ä ¼¼Æ÷¸¦ Çü¼ºÇÒ ¶§ ÀϾ´Â ºÐ¿­·Î¼­, ±× °á°ú ¿°»öüÀÇ ¼ö°¡ ü¼¼Æ÷¿¡ ºñÇÏ¿© ¹ÝÀ¸·Î °¨¼ÒÇÑ´Ù. ±×¸®°í ü¼¼Æ÷ ºÐ¿­ÀÇ ÇÙ ºÐ¿­¿¡ ¾Õ¼­ ÀÌÇü ÇÙ ºÐ¿­ÀÎ Á¦1ºÐ¿­ÀÌ Á¸ÀçÇÑ´Ù. ¼¼Æ÷ ºÐ¿­ °úÁ¤À» »ìÆìº¸¸é, ºÐ¿­¿¡¼­ ´ÙÀ½ ºÐ¿­±îÁöÀÇ ½Ã±â¸¦ °£±â ¶Ç´Â ÈÞÁö±â¶ó°í ÇÑ´Ù. ÀÌ °£±â¿¡´Â ¼¼Æ÷³»ÀÇ ¹°Áú´ë»ç³ª °íºÐÀÚ ÇÕ¼ºÀÌ ÀϾ°í, DNA µîÀÇ ¿°»öü ¹°ÁúÀÇ º¹Á¦µµ ÀϾ´Ù. ºÐ¿­ Á÷ÈÄ Çü¼ºµÈ µþ ¼¼Æ÷´Â °£±â¿¡ Á¡Â÷ Ä¿Á® ÇÙµµ 2¹è·Î ÀÚ¶õ´Ù. °£±â ±â°£Àº µ¿¹°, ½Ä¹°, Á¾, ǰÁ¾, Á¶Á÷, ±â°üÀÇ Â÷ÀÌ, ¿Âµµ, ¿µ¾ç µî¿¡ µû¶ó ´Ù¸£¸ç, ¼ö ½Ã°£ ¶Ç´Â ¼ö½Ê ½Ã°£¿¡ À̸£´Â °æ¿ì°¡ ¸¹´Ù. °£±âÀÇ ÇÙÀº ÇÙ ºÐ¿­À» ¾È ÇÒ »Ó ¹°Áú´ë»ç´Â ¿Õ¼ºÇÏ´Ù. À¯»çºÐ¿­¿¡ ÀÇÇØ ¿°»öü°¡ 2°³ÀÇ ÇÙÀ¸·Î ³ª´©¾îÁø ÈÄ ¼¼Æ÷Áú ºÐ¿­ÀÌ ÀϾ´Ù. ºÐ¿­±â¿¡ µé¾î¼­¸é ¿ì¼± ÇÙÀÌ Àü±â, Áß±â, Èıâ, ¸»±â¸¦ °ÅÃÄ µþ ¼¼Æ÷°¡ Çü¼ºµÈ´Ù. ¨ç Àü±â : ÇÙ ¾ÈÀÇ ¿°»ö»ç°¡ ³ª¼±ÇüÀ¸·Î ²¿¿© µÎ²®°í ª¾ÆÁ® ²ö ¸ð¾çÀÇ ¿°»öü°¡ µÈ´Ù. ¿°»öü´Â 2°³ÀÇ ¿°»ö ºÐü°¡ ºÙ¾î ÀÖ´Â ¸ð¾çÀ¸·Î µÇ¾î ÀÖÀ¸¸ç, µ¿½Ã¿¡ ÇÙ¸·, ÀÎÀÌ ¼Ò½ÇµÈ´Ù. °íµî½Ä¹°À» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ ¼¼Æ÷µéÀº ÇÑ ½ÖÀÇ Á߽ɸ³ÀÌ ÇÙ¸· ¹Ù±ùÂÊ¿¡ À§Ä¡ÇÑ´Ù. Á߽ɸ³Àº ¸ÕÀú ºÐ¿­ÇÑ ÈÄ À̵¿À» ½ÃÀÛÇÏ¿© ¾ç±Ø¿¡ µµ´ÞÇÑ´Ù. Áß½Éü°¡ ¾ø´Â ¼¼Æ÷¿¡¼­´Â ¾ç±ØÀ¸·ÎºÎÅÍ ¹æÃßü°¡ »ý±â±â ½ÃÀÛÇϴµ¥, À̸¦ ±Ø¸ð¶ó ÇÑ´Ù. µ¿½Ã¿¡ ¾ç±Ø ¶Ç´Â Áß½Éü¸¦ Áß½ÉÀ¸·Î ÇÏ¿© º°ºû ¸ð¾ç ¶Ç´Â ½Ç ¸ð¾ç ±¸Á¶¸¦ ÅëÆ²¾î ¼º»óü¶ó°í ÇÑ´Ù. À¯»çºÐ¿­ ±â°£ Áß Àü±â°¡ °¡Àå ±ä ½Ã°£À» Â÷ÁöÇÑ´Ù. ¨è Áß±â : ±¸ÇüÀÎ ÇÙÀÌ Å¸¿øÇüÀÌ µÇ¸ç ºñ¿°»öÁúÀº ¹æÃßÇüÀÇ ¹æÃßü¸¦ ÀÌ·ç¸é¼­ Àûµµ¸é
  • cell enclosure
    ¼¼Æ÷ ºÀÀÔü
    ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ¼¼Æ÷³»¿¡ ±èÀÚ ¾× µî¿¡ ÀÇÇØ ¿°»öµÈ °ú¸³»ó ¶Ç´Â ±× ¹ÛÀÇ Æ¯Â¡ÀÌ ÀÖ´Â ÇüŸ¦ º¸ÀÌ´Â ¼Òü. °£´ÜÈ÷ ºÀÀÔü¶ó°íµµ ÇÑ´Ù. ±¤°ßº´ µî ¹ÙÀÌ·¯½º º´À» Áø´ÜÇÏ´Â µ¥ ÀÌ¿ëµÇ´Â ¼¼Æ÷ ºÀÀÔüÀÇ º»·¡ ÇüÅ¿¡ °üÇÑ ³íÀǰ¡ ¸¹¾ÒÀ¸³ª, Áö±ÝÀº ¹ÙÀÌ·¯½º º´ÀÇ º´¿øÃ¼ÀÓÀÌ È®ÀεǾú´Ù. ¼¼Æ÷ ºÀÀÔü¿¡´Â ¼¼Æ÷Áú³» ºÀÀÔü¿Í ¼¼Æ÷ÇÙ³» ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷Áú³» ºÀÀÔü¿¡´Â õ¿¬µÎ, ¿ìµÎÀÇ °¡¸£´Ï¿¡¸® ¼Òü, ±¤°ßº´ÀÇ ³×±×¸® ¼Òü µîÀÌ ÀÖ´Ù. À̵éÀº È£»ê¼º, ¿øÇü, ±ÕÁú ¶Ç´Â °ú¸³»ó ±¸Á¶¸¦ °¡Áø °Í°ú Æ®¶óÄÚ¸¶ÀÇ ÇÁ·Î¹Ùüũ ¼Òü µî È£¿°±â¼ºÀ¸·Î º¹ÀâÇÑ ÇüÀ» °¡Áø °ÍÀÌ ÀÖ´Ù. ¼¼Æ÷ÇÙ³» ºÀÀÔü¿¡´Â Ç츣Æä½º À¯¹ß ¹ÙÀÌ·¯½º·Î Çü¼ºµÈ ºÀÀÔü°¡ ÀÖ´Ù. ¼¼Æ÷ ºÀÀÔü¸¦ ÇÔÀ¯ ³»¿ë¹°¿¡ µû¶ó ºÐ·ùÇϸé, ¹ÙÀÌ·¯½º°¡ ¸ðÀÎ °Í°ú ¹ÙÀÌ·¯½º ±¸¼º ¹°Áú·Î µÈ °ÍÀÌ ¸ðÀÎ °Í, ±×¸®°í ¹ÙÀÌ·¯½ºÀÇ ¼ººÐ°ú °ü·ÃÀÌ ¾ø´Â ƯÀ¯ÇÑ ´Ü¹éÁú·Î ÀÌ·ç¾îÁø °Í µî 3Á¾·ù·Î ³ª´¶´Ù. ¼¼Æ÷ ºÀÀÔüÀÇ Çü¼ºÀº ÁÖ·Î ¹ÙÀÌ·¯½ºÀÇ °¨¿°°ú °ü·ÃµÇ³ª À̿ܿ¡µµ Áß±Ý¼Ó µîÀÇ ¾àǰ Åõ¿©³ª ¼¼Æ÷´ë»ç Àå¾Ö¸¦ ÀÏÀ¸Å°´Â °Í¿¡ ÀÇÇÏ¿© ³ªÅ¸³ª±âµµ ÇÑ´Ù. ¿¹¸¦ µé¸é, ÁßÃ߽Űæ°èÀÇ ÁúȯÀÎ ÆÄŲ½¼ º´ÀÇ °æ¿ì ½Å°æ¼¼Æ÷³»¿¡¼­ ·¹ºß ¼Òü¶ó´Â ¼Òü¸¦, ¹Ì¿ÀŬ·Î´©½º °£Áú ȯÀÚÀÇ ³ú³ª ô¼öÀÇ ½Å°æ¼¼Æ÷³»¿¡¼­´Â ¹Ì¿ÀŬ·Î´©½º ¼Òü¸¦ º¼ ¼ö Àִµ¥ À̵éÀº ¸ðµÎ ¼¼Æ÷Áú³» ºÀÀÔüÀÌ´Ù.
  • cell fusion
    ¼¼Æ÷ ÀÀÇÕ, ¼¼Æ÷ À¶ÇÕ
    µÎ Á¾·ù ÀÌ»óÀÇ ¼¼Æ÷¸¦ ¹ÙÀÌ·¯½º,
  • cell harverter
    ¼¼Æ÷ ȸ¼ö±â
    ´Ù¼öÀÇ ¼¼Æ÷ ¹è¾ç ¿ë±â¿¡¼­ µ¿½Ã¿¡ ¹è¾çµÈ ´É·üÀÌ ÁÁÀº ¼¼Æ÷¸¦ äÃëÇÏ´Â ±â±âÀÇ ÃÑĪ.
  • cell hybridization
    ¼¼Æ÷ ÇÏÀ̺긮µå Çü¼º
  • cell injury
    ¼¼Æ÷ ¼Õ»ó
  • cell interface
    ¼¼Æ÷ »çÀÌ ¸é, ¼¼Æ÷ °£¸é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
diffusing factor <enzyme> Enzyme that degrades hyaluronic acid, found in lysosomes.
(18 Nov 1997)
direct lytic factor of cobra venom A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent.
Synonym: cobra toxin, direct lytic factor of cobra venom.
(05 Mar 2000)
Duran-Reynals permeability factor <enzyme> Enzyme that degrades hyaluronic acid, found in lysosomes.
(18 Nov 1997)
duty factor <radiobiology> Ratio of the duration of time when a system is actually operating to the total time for a complete cycle of the system. For example: if a tokamak experiment runs for 5 seconds and then sits for 500 seconds while the power supplies are recharged, then the duty factor is 1%. Similar to capacity factor for powerplants.
Synonym: duty cycle.
(09 Oct 1997)
q-factor <radiobiology> Ratio of power produced by fusion to power put into the reactor to heat the plasma and drive the magnetic fields.
Q = 1 is the definition of scientific breakeven, where power out = power in. Economical fusion will require Q significantly greater than 1. Fortunately Q increases dramatically as the plasma parameters approach the Lawson criterion for ignition. Power to drive the magnetic fields is frequently ignored in discussions of Q, with the justification that a steady-state, continuous-output fusion reactor will have superconducting magnet coils.
(15 Dec 1997)
quality factor <radiobiology> (Q) A multiplying factor used with absorbed dose to convert to dose equivalent and therefore to express the radiation's effectiveness in causing biological effects.
(16 Dec 1997)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
initiation factor One of several soluble proteins involved in the initiation of protein or RNA synthesis.
(05 Mar 2000)
insulin activating factor <chemical> Activates insulin gene transcription in pancreatic beta cells.
Synonym: insaf
(05 Dec 1998)
insulin-antagonizing factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á